| INVENTIVA S.A.(PROM.)-,01 |
| Frankreich |
| Gesundheit |
| FR0013233012 / A2DLV9 |
| 6IV (Frankfurt) |
| FRA:6IV, ETR:6IV, 6IV:GR |
| - |
| https://inventivapharma.c.. |
|
Inventiva S.A. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with significant unmet medical needs in fibrosis, lysosomal storage disorders, and oncology. Its lead candidate, Lanifibrano..
>Volltext.. |
| 968.54 Mio. EUR |
| 870.4 Mio. EUR |
| 4.51 Mio. EUR |
| - |
| -356.2 Mio. EUR |
| -1.91 EUR |
| - |
| 99.88 Mio. EUR |
| -105.51 Mio. EUR |
| - |
| -51.26% |
| -92.24% |
| - |
| - |
| - |
| - |
| INVENTIVA |
| 08.04.26 |
|